For the millions of older adults quietly questioning whether a pill they've taken for decades still earns its place in their medicine cabinet, this trial delivers a clinically meaningful answer. The assumption that stopping a statin late in life courts cardiovascular catastrophe — long embedded in prescribing culture — now faces its most rigorous challenge yet from a randomised controlled design.
The SAGA/SITE trial enrolled adults aged 75 and older who were taking statins solely for primary prevention — meaning they had never experienced a heart attack, stroke, or other confirmed atherosclerotic cardiovascular event. Across multiple centres using a pragmatic open-label design, participants were randomised either to discontinue or continue statin therapy and followed for three years. The primary endpoint was all-cause mortality. The key result: discontinuation was non-inferior to continuation, meaning the trial found no statistically meaningful increase in death risk among those who stopped. This is not a trivial finding — it pertains specifically to the primary prevention population, where the calculus of benefit versus polypharmacy burden is most contested.
This result lands in a landscape where statin prescribing in the elderly has expanded steadily despite thin randomised evidence specific to this age group. Most landmark statin trials enrolled predominantly middle-aged populations, and extrapolating their cardiovascular risk reduction data to adults over 75 has always required inferential leaps. Mechanistically, the benefit of statins is largely proportional to baseline cardiovascular risk and the remaining time horizon to accrue that benefit — both factors that shift meaningfully past 75. Competing mortality risks, statin-related muscle effects, drug interactions from polypharmacy, and quality-of-life considerations all argue for reassessment. Importantly, this trial addresses primary prevention only; the evidence base for secondary prevention in older adults remains substantially stronger and should not be conflated with these findings. The non-inferiority design means absence of harm was demonstrated, not superiority of stopping — a distinction clinicians should communicate carefully to patients.
